Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer (SHAPE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01658930|
Recruitment Status : Active, not recruiting
First Posted : August 7, 2012
Last Update Posted : February 15, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer||Procedure: Radical Hysterectomy + pelvic lymph node dissection Procedure: Simple hysterectomy + pelvic lymph node dissection||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||700 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-Risk Early Stage Cervical Cancer (SHAPE)|
|Actual Study Start Date :||August 2, 2012|
|Estimated Primary Completion Date :||June 30, 2023|
|Estimated Study Completion Date :||December 31, 2023|
|Active Comparator: Radical Hysterectomy||
Procedure: Radical Hysterectomy + pelvic lymph node dissection
This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
|Experimental: Simple Hysterectomy||
Procedure: Simple hysterectomy + pelvic lymph node dissection
This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
- Pelvic recurrence rate at 3 years [ Time Frame: 7 years ]Pelvic relapse-free survival (PRFS), the primary endpoint of this study, is defined as the time from randomization to the time of documented evidence of recurrence within the pelvic field.
- Efficacy comparison between treatment arms [ Time Frame: 7 years ]
compare the two treatment arms with respect to:
- pelvic relapse-free survival
- Extra pelvic relapse-free survival
- Relapse-free survival (any site)
- Overall survival
- Treatment-related adverse events
- Patient Reported Outcomes including global quality of life and measures of sexual health
- Cost-effectiveness and cost-utility
- To observe the rates of the following in this patient population: sentinel node detection.
- Parametrial involvement
- Involvement of surgical margins
- Pelvic node involvement
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Gender Based Eligibility:||Yes|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.
Patient has been classified as low-risk early-stage cervical cancer. These patients include:
• FIGO Stage IA2 [FIGO Annual Report, 2009], defined as:
o evidence of disease by microscopy;
for patients who underwent a LEEP or cone:
- histologic evidence of depth of stromal invasion > 3.0 and ≤ 5.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen NB: the maximum depth of stromal invasion must be ≤ 10 mm.
- histologic evidence of lateral extension that is ≤ 7.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen; and
- negative margins (patients with positive margins are considered IB1, see below)
for patients who underwent a cervical biopsy only:
radiologic evidence of less than 50% stromal invasion based on pelvic MRI
• FIGO Stage IB1 [FIGO Annual Report, 2009] with favorable (low risk) features, defined as:
- measured stromal invasion and lateral extension that meet the criteria for IA2 (see above) but with positive margins;
- evidence of disease by clinical exam; lesion must clinically measure ≤ 20 mm
- evidence of disease by microscopy;
for patients who underwent a LEEP or cone:
- histologic evidence of depth of stromal invasion between 5.1-10 mm and/or lateral extension between 7.1-20.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen
- for patients who underwent a cervical biopsy only:
- radiologic evidence of less than 50% stromal invasion based on pelvic MRI
- lateral extension ≤ 20 mm based on clinical exam or radiologic imaging.
In addition to above criteria on maximal stromal invasion of ≤ 10 mm, the lesion must be no larger than 20 mm in any dimension by any assessment method (MRI, clinical or histological exam). To ensure patients meet this criterion, investigators may need to sum the lesion measurements from biopsy and other methods that evaluate it in the same plane.
Patients are eligible irrespective of the presence or absence of lymph-vascular space involvement (LVSI).
- Physical examination, recto-vaginal examination and visualization of the cervix by speculum or colposcopic examination have been done after the initial diagnostic procedure (LEEP, cone or biopsy) and prior to randomization.
- Chest x-ray or CT scan of chest AND pelvic MRI* done after initial diagnostic procedure (LEEP, cone or biopsy) and prior to randomization.
The CT should be a 16 slice (or higher) helical scanner. Oral and intravenous contrasts are preferred (unless there is a contraindication to the use of contrast) with scan obtained in the portal phase at a slice thickness of 5mm or lower Pelvic MRI should be performed on a 1.5 or 3 Tesla magnet with pelvic phased-array coils. The MR pulse sequences will consist of T1 gradient echo in the axial plane at 5 mm slice thickness and fast spin echo in the axial, sagittal, and coronal planes at 4 mm slice thickness. The short axis (perpendicular to the tumour's long axis) with a 3 mm slice thickness is required in the best plane to show the maximum thickness of stromal invasion. Use of an anti-peristaltic agent is mandatory while intravenous use of gadolinium or diffusion-weighted imaging (DWI) is optional.
* Note: pelvic MRI is optional if the patient has stage IA2 disease and underwent a LEEP or cone.
- After consideration of a patient's medical history, physical examination and laboratory testing, patients must be suitable candidates for surgery as defined by the attending physician / investigator.
- Patients must have no desire to preserve fertility.
- Patients fluent in English or French must be willing to complete the Quality of Life Questionnaire. The baseline assessments must be completed within 6 weeks prior to randomization. Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible. As additional GCIG groups join the study, more translations of some of the questionnaires may be added.
Patients fluent in English or French who reside in Canada and the United Kingdom must agree to participate in the economic evaluation component of this trial and complete the Health Economics Questionnaire. Similarly, patients fluent in English or French accrued from other GCIG groups who are participating in the economic evaluation must be willing to complete the Health Economics Questionnaires.
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate.
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
- Surgery is to be done within 20 weeks of initial diagnosis (NO EXCEPTIONS). The 20-week period includes time required for diagnosis, referral, diagnostic staging, randomization and scheduling of the surgical procedure.
- Patients must be ≥ 18 years old.
- Patients with FIGO 1A1 disease [FIGO Annual Report, 2009].
- History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours, Hodgkin's lymphoma or non-Hodgkin's lymphoma curatively treated with no evidence of disease for > 5 years.
- Patients with evidence of lymph node metastasis on preoperative imaging or histology.
- Patients who have had or will receive neoadjuvant chemotherapy.
- Patients who are pregnant.
- Patients for whom adjuvant radiation and/or chemotherapy is planned.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01658930
|Study Chair:||Marie Plante||Canadian Cancer Trials Group|
|Study Chair:||Gwenael Ferron||France-GINECO|
|Study Chair:||Jae-Weon Kim||Korean Gynecology Oncology Group|
|Study Chair:||Christian Marth||Arbeitsgemeinschaft Gynaekologische Onkologie Austria|
|Study Chair:||John Tidy||Institute of Cancer Research, United Kingdom|
|Study Chair:||Noreen Gleeson||Ireland Co-operative Oncology Research Group|
|Study Chair:||Frederic Goffin||Belgian Gynaecological Oncology Group|
|Study Chair:||Cor de Kroon||The Dutch Gynecological Oncology Group (DGOG)|
|Study Chair:||Xiaohua Wu||Fudan University|
|Study Chair:||Sven Mahner||AGO Germany|
|Study Chair:||Brynhildur Eyjolfsdottir||Oslo University Hospital|
|Study Chair:||Alexey Shevchuk||Hertzen Institute, Moscow|
|Responsible Party:||Canadian Cancer Trials Group|
|Other Study ID Numbers:||
|First Posted:||August 7, 2012 Key Record Dates|
|Last Update Posted:||February 15, 2023|
|Last Verified:||July 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Uterine Cervical Neoplasms
Uterine Cervical Diseases
Genital Neoplasms, Female
Neoplasms by Site
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications